

## **Supplementary File**

**Table S1.** Classification of severe AEs.

**Table S2.** Multiple regression analysis for common AEs by sex (reference: female), age (years), symptom onset (number of days), and dose series of vaccine (coding the first dose as 0 and the second dose as 1) as covariates. Dependent variables: incidence, independent variables: sex (coding male as 1 and female as 0), age (years), symptom onset (number of days), and dose series of vaccine.

**Table S1.** Classification of severe AEs.

Category	Severe AEs
Central nervous disorders	Bell's palsy Stroke, ischemia Stroke, hemorrhagic Encephalitis/myelitis/encephalomyelitis Cerebral venous sinus thrombosis Convulsion/seizures Guillain–Barré syndrome Transverse myelitis Acute disseminated encephalomyelitis Narcolepsy/cataplexy
Respiratory disorders	Pulmonary embolism Acute respiratory distress syndrome (ARDS)
Cardiac disorders	Acute myocardial infarction Myocarditis/pericarditis
Gastrointestinal disorders	Appendicitis
Hematologic disorders	Anemia Lymphadenopathy Lymphopenia Neutropenia Other thrombosis Thrombocytopenia Deep vein thrombosis
Others	Anaphylaxis Multisystem inflammatory syndrome in children/adults Death

**Table S2.** Multiple regression analysis for common AEs by sex (reference: female), age (years), symptom onset (number of days), and dose series of vaccine (coding the first dose as 0 and the second dose as 1) as covariates. Dependent variables: incidence, independent variables: sex (coding male as 1 and female as 0), age (years), symptom onset (number of days), and dose series of vaccine.

		Dizziness			Syncope			Nausea	
	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P
Sex (M/F)	0.680	0.597 – 0.773	< 0.001	0.618	0.532 – 0.717	< 0.001	0.755	0.641 – 0.890	0.001
Age (years)	1.184	1.118 – 1.254	< 0.001	1.119	1.049 – 1.195	0.001	1.055	0.981 – 1.133	0.147
Onset (days)	0.872	0.841 – 0.905	< 0.001	0.678	0.618 – 0.745	< 0.001	0.926	0.894 – 0.958	< 0.001
Dose series <sup>a</sup>	0.574	0.500 – 0.661	< 0.001	0.483	0.407 – 0.572	< 0.001	0.981	0.829 – 1.160	0.820
		Headache			Pyrexia			Chest pain	
	OR	95% CI	p	OR	95% CI	p	OR	95% CI	p
Sex (M/F)	0.911	0.770 – 1.077	0.276	1.329	1.113 – 1.587	0.002	3.446	2.822 – 4.207	< 0.001
Age (years)	0.927	0.861 – 0.998	0.045	0.898	0.831 – 0.971	0.007	1.254	1.155 – 1.361	< 0.001
Onset (days)	1.000	0.986 – 1.014	0.968	1.012	1.000 – 1.025	0.047	1.020	1.008 – 1.032	0.001
Dose series <sup>a</sup>	1.796	1.518 – 2.125	< 0.001	4.371	3.613 – 5.287	< 0.001	4.626	3.804 – 5.626	< 0.001
		Loss of consciousness			Pallor			Unresponsive to stimuli	
	OR	95% CI	p	OR	95% CI	p	OR	95% CI	p
Sex (M/F)	0.853	0.705 – 1.033	0.104	3.593	0.675 – 0.993	0.042	0.640	0.497 – 0.824	0.001
Age (years)	1.283	1.176 – 1.400	< 0.001	1.037	1.022 – 1.212	0.014	1.137	1.019 – 1.269	0.022
Onset (days)	0.806	0.742 – 0.876	< 0.001	1.007	0.496 – 0.692	< 0.001	0.752	0.656 – 0.862	< 0.001
Dose series <sup>*</sup>	0.602	0.485 – 0.746	< 0.001	1.130	0.374 – 0.596	< 0.001	0.507	0.378 – 0.679	< 0.001
		Fall			Troponin increased			Tremor	
	OR	95% CI	p	OR	95% CI	p	OR	95% CI	p
Sex (M/F)	0.699	0.539 – 0.908	0.007	8.711	5.650 – 13.431	< 0.001	0.787	0.589 – 1.051	0.104
Age (years)	0.863	0.790 – 0.942	0.001	1.441	1.258 – 1.650	< 0.001	1.233	1.083 – 1.405	0.002
Onset (days)	1.104	0.985 – 1.238	0.088	1.022	1.005 – 1.040	0.010	0.967	0.926 – 1.010	0.128
Dose series <sup>*</sup>	0.686	0.518 – 0.910	0.009	8.558	5.847 – 12.524	< 0.001	0.843	0.623 – 1.140	0.268
		Urticaria			Flushing			Malaise	
	OR	95% CI	p	OR	95% CI	p	OR	95% CI	p
Sex (M/F)	1.171	0.873 – 1.572	0.291	0.869	0.638 – 1.184	0.373	0.967	0.708 – 1.321	0.832
Age (years)	0.851	0.747 – 0.970	0.016	1.134	0.988 – 1.302	0.075	1.077	0.937 – 1.237	0.297

Onset (days)	1.018	0.997 – 1.039	0.089	0.673	0.539 – 0.842	0.001	1.000	0.972 – 1.028	0.999
Dose series*	0.798	0.584 – 1.091	0.157	0.423	0.286 – 0.627	< 0.001	1.191	0.867 – 1.635	0.281

\*Dose series: The 1st or 2nd dose

OR: Odds Ratio, 95% CI: 95% confidence intervals, *p*: *p*-values